You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMagnesium salicylate
Accession NumberDB01397
TypeSmall Molecule
GroupsApproved
Description

Magnesium salicylate is a common analgesic and non-steroidal anti-inflammatory drug (NSAID) used to treat mild to moderate muscular pain. It is also used to treat headaches, general back pain, and certain joint pains like arthritis.

It is found in a variety of over-the-counter (OTC) medications as an anti-inflammatory, primarily for back-pain relief. Magnesium Salicylate can be an effective OTC alternative to prescription NSAIDs, with both anti-inflamatory and pain-relieving effects.

Though the recommended doseage is 1160 mg every six hours, per package directions of the Doan’s OTC brand (580 mg magnesium salicylate tetrahydrate, equivalent to 934.4 mg anhydrous magnesium salicylate), effective pain relief is often found with a half dosage, with reduced anti-inflammatory results.

Structure
Thumb
Synonyms
Magnesium salicylate anhydrous
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Back-ese M Tab 325mgtablet325 mgG.T. Fulford Pharmaceuticals1985-12-311998-06-25Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Arthriten Tabletstablet325 mgoralAlva Amco Pharmacal Companies, Inc.2003-05-152006-07-27Canada
Back-ese M Tablets 325 mgtablet325 mgoralDannorth Laboratories Inc.1980-12-312000-07-19Canada
Backache Aidtablet, film coated580 mg/1oralL&R Distributors, Inc.1998-11-07Not applicableUs
Backache Relieftablet, film coated580 mg/1oralWOONSOCKET PRESCRIPTION CENTER,INCORPORATED1998-11-07Not applicableUs
Backache Relieftablet, film coated580 mg/1oralRite Aid1998-11-07Not applicableUs
Backache Relief Extra Strengthtablet580 mg/1oralWALGREEN CO.1998-11-07Not applicableUs
Backache Relief Extra Strengthtablet, film coated580 mg/1oralL.N.K. International, Inc.1998-11-07Not applicableUs
Doan's Backache Pills 325mgtablet325 mgoralNovartis Consumer Health Canada Inc.1988-12-311998-07-08Canada
Doans Extra Strengthtablet580 mg/1oralDucere Pharma LLC2013-05-15Not applicableUs
Extra Strength Backache Reliefcapsule580 mg/1oralFamily Dollar1998-11-07Not applicableUs
Herbogesictablet650 mgoralSeroyal International Inc.1988-12-312009-07-06Canada
Kneerelief Tabletstablet650 mgoralAlva Amco Pharmacal Companies, Inc.2003-05-152006-07-27Canada
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
Back ReliefNorth Safety Products LLC
Diurex Water PillsAlva Amco Pharmacal Companies, Inc.
Medique Back Pain OffUnifirst First Aid Corporation
Otis Clapp Back QuellUnifirst First Aid Corporation
Pain Aid BrfZee Medical Inc
Pamprin Cramp Menstrual Pain ReliefChattem, Inc.
Trilisate TabPurdue Pharma
Vica-cetProvision Medical Products
Salts
Name/CASStructureProperties
Magnesium salicylate tetrahydrate
18917-95-8
Thumb
  • InChI Key: CWQGWAKCTBFURY-UHFFFAOYSA-J
  • Monoisotopic Mass: 368.05938842
  • Average Mass: 368.577
DBSALT001864
Categories
UNIIJQ69D454N1
CAS number18917-89-0
WeightAverage: 298.531
Monoisotopic: 298.03277995
Chemical FormulaC14H10MgO6
InChI KeyInChIKey=MQHWFIOJQSCFNM-UHFFFAOYSA-L
InChI
InChI=1S/2C7H6O3.Mg/c2*8-6-4-2-1-3-5(6)7(9)10;/h2*1-4,8H,(H,9,10);/q;;+2/p-2
IUPAC Name
magnesium(2+) ion bis(2-hydroxybenzoate)
SMILES
[Mg++].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as salicylic acids. These are ortho-hydroxylated benzoic acids.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzoic acids and derivatives
Direct ParentSalicylic acids
Alternative Parents
Substituents
  • Salicylic acid
  • Benzoic acid
  • Benzoyl
  • Phenol
  • Vinylogous acid
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organic salt
  • Organooxygen compound
  • Carbonyl group
  • Organic zwitterion
  • Aromatic homomonocyclic compound
Molecular FrameworkNot Available
External DescriptorsNot Available
Pharmacology
IndicationMagnesium salicylate is a common analgesic and non-steroidal anti-inflammatory drug (NSAID) used to treat mild to moderate muscular pain
PharmacodynamicsNot Available
Mechanism of actionMost NSAIDs act as nonselective inhibitors of the enzyme cyclooxygenase (COX), inhibiting both the cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) isoenzymes. COX catalyzes the formation of prostaglandins and thromboxane from arachidonic acid (itself derived from the cellular phospholipid bilayer by phospholipase A2). Prostaglandins act (among other things) as messenger molecules in the process of inflammation.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
Pathways
PathwayCategorySMPDB ID
Magnesium salicylate Action PathwayDrug actionSMP00698
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.5741
Blood Brain Barrier+0.829
Caco-2 permeable+0.5941
P-glycoprotein substrateNon-substrate0.6758
P-glycoprotein inhibitor INon-inhibitor0.9704
P-glycoprotein inhibitor IINon-inhibitor0.9768
Renal organic cation transporterNon-inhibitor0.8975
CYP450 2C9 substrateNon-substrate0.7872
CYP450 2D6 substrateNon-substrate0.9101
CYP450 3A4 substrateNon-substrate0.7282
CYP450 1A2 substrateNon-inhibitor0.8837
CYP450 2C9 inhibitorNon-inhibitor0.5705
CYP450 2D6 inhibitorNon-inhibitor0.9113
CYP450 2C19 inhibitorNon-inhibitor0.8537
CYP450 3A4 inhibitorNon-inhibitor0.9421
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9021
Ames testNon AMES toxic0.9695
CarcinogenicityNon-carcinogens0.8587
BiodegradationReady biodegradable0.8277
Rat acute toxicity2.3552 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.952
hERG inhibition (predictor II)Non-inhibitor0.9555
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tabletoral
Tablet325 mg
Tabletoral325 mg
Tablet, film coatedoral580 mg/1
Tabletoral580 mg/1
Tablet, coatedoral
Capsuleoral580 mg/1
Tabletoral650 mg
Tablet, film coatedoral
Prices
Unit descriptionCostUnit
Tricosal 1000 mg tablet1.23USD tablet
Choline mag trisal 1 gm tablet1.15USD tablet
Choline mag trisal 750 mg tablet0.81USD tablet
Novasal 600 mg tablet0.75USD tablet
Choline mag trisal 500 mg tablet0.64USD tablet
Doan's ex strength 580 mg tablet0.22USD tablet
CVS Pharmacy backache rlf 580 mg caplet0.18USD caplet
Doan's regular 325 mg tablet0.18USD tablet
Keygesic-10 650 mg tablet0.05USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0686 mg/mLALOGPS
logP2.86ALOGPS
logP1.98ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)2.79ChemAxon
pKa (Strongest Basic)-6.3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area60.36 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity46.13 m3·mol-1ChemAxon
Polarizability12.38 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Satishchandra P. Patel, Vinayak T. Bhalani, “Solid choline magnesium salicylate composition and method of preparing same.” U.S. Patent US5043168, issued May, 1954.

US5043168
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AbciximabMagnesium salicylate may increase the anticoagulant activities of Abciximab.
AcenocoumarolMagnesium salicylate may increase the anticoagulant activities of Acenocoumarol.
AcetazolamideThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Acetazolamide.
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Magnesium salicylate.
AlfacalcidolThe serum concentration of Magnesium salicylate can be increased when it is combined with Alfacalcidol.
AlteplaseThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Alteplase.
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Magnesium salicylate.
Ammonium chlorideThe serum concentration of Magnesium salicylate can be increased when it is combined with Ammonium chloride.
AmrinoneThe risk or severity of adverse effects can be increased when Amrinone is combined with Magnesium salicylate.
AnistreplaseThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Anistreplase.
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Magnesium salicylate.
CalcitriolThe serum concentration of Magnesium salicylate can be increased when it is combined with Calcitriol.
Citric AcidMagnesium salicylate may increase the anticoagulant activities of Citric Acid.
DalteparinMagnesium salicylate may increase the anticoagulant activities of Dalteparin.
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Magnesium salicylate.
DesmopressinThe risk or severity of adverse effects can be increased when Desmopressin is combined with Magnesium salicylate.
DexketoprofenThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Dexketoprofen.
DiclofenamideThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Diclofenamide.
DicoumarolMagnesium salicylate may increase the anticoagulant activities of Dicoumarol.
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Magnesium salicylate.
Edetic AcidMagnesium salicylate may increase the anticoagulant activities of Edetic Acid.
EltrombopagThe serum concentration of Eltrombopag can be decreased when it is combined with Magnesium salicylate.
EnoxaparinMagnesium salicylate may increase the anticoagulant activities of Enoxaparin.
EthoxzolamideThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Ethoxzolamide.
Ethyl biscoumacetateMagnesium salicylate may increase the anticoagulant activities of Ethyl biscoumacetate.
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Magnesium salicylate.
FludrocortisoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fludrocortisone.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Magnesium salicylate.
Fondaparinux sodiumMagnesium salicylate may increase the anticoagulant activities of Fondaparinux sodium.
GabapentinMagnesium salicylate may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.
Ginkgo bilobaGinkgo biloba may increase the anticoagulant activities of Magnesium salicylate.
HeparinMagnesium salicylate may increase the anticoagulant activities of Heparin.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Magnesium salicylate.
Insulin HumanMagnesium salicylate may increase the hypoglycemic activities of Insulin Regular.
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Magnesium salicylate.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Magnesium salicylate.
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Magnesium salicylate.
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Magnesium salicylate.
Lipoic AcidMagnesium salicylate can cause a decrease in the absorption of Lipoic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Magnesium salicylate.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Magnesium salicylate.
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Magnesium salicylate.
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Magnesium salicylate.
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Magnesium salicylate.
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Magnesium salicylate.
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Magnesium salicylate.
OxytetracyclineMagnesium salicylate can cause a decrease in the absorption of Oxytetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
PerhexilineThe risk or severity of adverse effects can be increased when Perhexiline is combined with Magnesium salicylate.
PerindoprilMagnesium salicylate may decrease the antihypertensive activities of Perindopril.
PhenindioneMagnesium salicylate may increase the anticoagulant activities of Phenindione.
PhenprocoumonMagnesium salicylate may increase the anticoagulant activities of Phenprocoumon.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Magnesium salicylate.
PrenylamineThe risk or severity of adverse effects can be increased when Prenylamine is combined with Magnesium salicylate.
ProbenecidThe therapeutic efficacy of Probenecid can be decreased when used in combination with Magnesium salicylate.
RaltegravirThe serum concentration of Raltegravir can be decreased when it is combined with Magnesium salicylate.
ReteplaseThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Reteplase.
RidogrelThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Ridogrel.
RisedronateThe risk or severity of adverse effects can be increased when Risedronate is combined with Magnesium salicylate.
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Magnesium salicylate.
StreptokinaseThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Streptokinase.
SulodexideMagnesium salicylate may increase the anticoagulant activities of Sulodexide.
TenecteplaseThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Tenecteplase.
TorasemideMagnesium salicylate may decrease the diuretic activities of Torasemide.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Magnesium salicylate.
TriethylenetetramineThe serum concentration of Magnesium salicylate can be decreased when it is combined with Triethylenetetramine.
UrokinaseThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Urokinase.
Valproic AcidThe serum concentration of Valproic Acid can be increased when it is combined with Magnesium salicylate.
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Magnesium salicylate.
WarfarinMagnesium salicylate may increase the anticoagulant activities of Warfarin.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Graham GG, Scott KF: Mechanisms of action of paracetamol and related analgesics. Inflammopharmacology. 2003;11(4):401-13. [PubMed:15035793 ]
  2. Fiebich BL, Chrubasik S: Effects of an ethanolic salix extract on the release of selected inflammatory mediators in vitro. Phytomedicine. 2004 Feb;11(2-3):135-8. [PubMed:15070163 ]
  3. Chae HJ, Chae SW, Reed JC, Kim HR: Salicylate regulates COX-2 expression through ERK and subsequent NF-kappaB activation in osteoblasts. Immunopharmacol Immunotoxicol. 2004 Feb;26(1):75-91. [PubMed:15106733 ]
  4. Wu KK: Aspirin and other cyclooxygenase inhibitors: new therapeutic insights. Semin Vasc Med. 2003 May;3(2):107-12. [PubMed:15199473 ]
  5. Elvira C, Gallardo A, Lacroix N, Schacht E, San Roman J: Incorporation of salicylic acid derivatives to hydrophilic copolymer systems with biomedical applications. J Mater Sci Mater Med. 2001 Jun;12(6):535-42. [PubMed:15348270 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Moon C, Ahn M, Jee Y, Heo S, Kim S, Kim H, Sim KB, Koh CS, Shin YG, Shin T: Sodium salicylate-induced amelioration of experimental autoimmune encephalomyelitis in Lewis rats is associated with the suppression of inducible nitric oxide synthase and cyclooxygenases. Neurosci Lett. 2004 Feb 12;356(2):123-6. [PubMed:14746879 ]
  2. Graham GG, Scott KF: Mechanisms of action of paracetamol and related analgesics. Inflammopharmacology. 2003;11(4):401-13. [PubMed:15035793 ]
  3. Sun R, Carlson NG, Hemmert AC, Kishore BK: P2Y2 receptor-mediated release of prostaglandin E2 by IMCD is altered in hydrated and dehydrated rats: relevance to AVP-independent regulation of IMCD function. Am J Physiol Renal Physiol. 2005 Sep;289(3):F585-92. Epub 2005 Apr 19. [PubMed:15840771 ]
  4. Celik G, Pasaoglu G, Bavbek S, Abadoglu O, Dursun B, Mungan D, Misirligil Z: Tolerability of selective cyclooxygenase inhibitor, celecoxib, in patients with analgesic intolerance. J Asthma. 2005 Mar;42(2):127-31. [PubMed:15871445 ]
  5. Liu X, Lee TL, Wong PT: Cyclooxygenase-1 inhibition shortens the duration of diazepam-induced loss of righting reflex in mice. Anesth Analg. 2006 Jan;102(1):135-40. [PubMed:16368818 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
no
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Zhang Q, Huang Y, Zhao R, Liu G, Chen Y: Determining binding sites of drugs on human serum albumin using FIA-QCM. Biosens Bioelectron. 2008 Sep 15;24(1):48-54. doi: 10.1016/j.bios.2008.03.009. Epub 2008 Mar 21. [PubMed:18436441 ]
Comments
comments powered by Disqus
Drug created on July 08, 2007 11:04 / Updated on August 17, 2016 12:23